Board of directors

Magnus2

Magnus Persson

Chairman of the Board since 2016, born 1960. Member of the Remuneration Committee and the Drug Development Committee. Number of shares: 190 154

Magnus Persson is MD and associate professor in physiology at the Karolinska Institute in Stockholm. Persson has extensive experience of financing within the fields of medicine, life sciences and biotech. Persson has previously led development teams in clinical phase II and phase III programmes in the pharmaceutical industry and has founded and led private as well as public biotech and medtech companies, either as Chairman or Member of the Board, in Europe and the US. Persson has also been involved in multiple IPOs.

Persson is Chairman of the Board of Attgeno AB, Initiator Pharma AS, Eir Ventures Partners AB and associated companies and Board Member of Avalo Inc.

Independent in relation to the Company and its management and the Company’s major shareholders.

Karin L

Karin Leandersson

Board member since 2016, born 1972. Member of the Audit Committee. Number of shares: 2 500

Karin Leandersson is professor in Tumour Immunology at the Medical Faculty of Lund University. Leandersson has gained a wide range of cancer research experience in the fields of tumour immunology and tumour inflammation in solid tumours, mainly in breast cancer. Leandersson has also authored around 50 scientific publications in international journals.

Independent in relation to the Company and its management and the Company’s major shareholders.

Thoas F

Thoas Fioretos

Board member since 2010, born 1962. Member of the Remuneration Committee. Number of shares: 575 600

Thoas Fioretos is professor and physician at the Department of Clinical Genetics at Lund University. Fioretos’ research focuses on molecular and functional studies of genetic changes in leukaemia and how such changes can be used for diagnostic and therapeutic purposes. Fioretos has authored over 130 scientific publications and is one of the founders of Cantargia AB and the bio-IT company Qlucore AB. Fioretos is Board Member in Qlucore AB and alternate Board Member in Neodos AB.

Independent in relation to the Company and its management and the Company’s major shareholders.

Patricia Delaite 600 13

Patricia Delaite

Board member since 2017, born 1963. Member of the Drug Development Committee. Number of shares: 0

Patricia Delaite is MD and has an MBA from University of Geneva and Lausanne. Delaite is currently Chief Medical Officer at Nouscom in Basel, and has had leading positions at AMAL Therapeutics, Incytes International Biosciences, ARIAD Pharmaceuticals, Novartis, and Eli Lilly. Delaite also has 10 years of experience in clinical management from the University Hospital in Geneva.

Independent in relation to the Company and its management and the Company’s major shareholders.

Anders Martin Loef Red 05

Anders Martin-Löf

Board member since 2018, born 1971. Chairman of the Audit Committee. Number of shares: 50 000

Anders Martin-Löf has extensive experience as CFO for companies listed on the Stockholm stock exchange and has served as CFO for Oncopeptides AB, Wilson Therapeutics AB and RaySearch Laboratories AB. Martin-Löf has also held the position of Head of Investor Relations and different positions within business development at Swedish Orphan Biovitrum and is currently Board Member of Affibody Medical AB. Martin-Löf holds an MSc in Engineering Physics from the Royal Institute of Technology and a BSc in Business Administration and Economics from Stockholm University.

Independent in relation to the Company and its management and the Company’s major shareholders.

Flavia Borellini2

Flavia Borellini

Board member since 2020, born 1959. Chairman of the Drug Development Committee. Number of shares: 0

Flavia Borellini holds a PhD in Pharmaceutical Chemistry and Technology from the University of Modena in Italy.
Borellini has broad experience in oncology and other therapeutic areas and has held senior positions at Astra Zeneca (Global Franchise Head, Hematology and Vice President, Global Product and Portfolio Strategy), Acerta Pharma (CEO), ONYX Pharmaceuticals (Vice President, Program Leadership), and Roche/Genetech (Lifecycle Leader).
Borellini serves as a Member of the Board of Directors of Kartos Therapeutics, Revolution Medicines and Viracta.

Independent in relation to the Company and its management and the Company’s major shareholders.

Magnus Nilsson Hemsida

Magnus Nilsson

Board member since 2021, born 1956. Member of the Audit Committee. Number of shares: 100 000

Magnus Nilsson is founder, previously President and CEO, and since 2020 Senior Advisor at XVIVO Perfusion. Nilsson has also been President and CEO of Vitrolife and held prior to that various positions as Project Manager for drug development projects at Pharmacia & Upjohn, Pharmacia, and Karo Bio. Nilsson serves as a Member of the Board of Directors of Corline Biomedical. Nilsson is Doctor of Medicine (Med Dr Sc) from Uppsala University and has published over twenty scientific articles.

Independent in relation to the Company and its management and the Company’s major shareholders.

Damian Hemsida

Damian Marron

Board member since 2021, born 1962. Chairman of the Remuneration Committee. Number of shares: 0

Damian Marron has extensive experience as a Board Member and CEO within the life science industry, with a successful track record of leadership and value creation in public and private biotechnology companies. Marron has held positions as CEO and Executive Vice President in several biotech companies. He is currently Chairman of the Board of Targovax ASA, Imophoron Ltd, CytoseeK Ltd and Board Member of Bone Therapeutics and Resolys Bio, and Head of Biopharma at Treehill Partners.
Marron holds a BSc degree in Pharmacology from the University of Liverpool.

Independent in relation to the Company and its management and the Company’s major shareholders.